There’s growing evidence that GLP-1 drugs, which include Ozempic, Mounjaro (Dr Varipapa’s favorite), Zepbound and Wegovy, may benefit the brain.
Semaglutide, the active ingredient in Ozempic and Wegovy, appeared to reduce the risk of Alzheimer’s disease in people with Type 2 diabetes, according to a study published Thursday in the journal Alzheimer’s & Dementia.
The study adds to evidence that GLP-1 drugs — the class of medications that also includes Mounjaro and Zepbound — may benefit the brain.
CNMRI: Neurology, Sleep Medicine, MRI 